FDA

You might think Big Pharma would give up its longstanding fight against Canadian drug reimportation — now that both John McCain and Barack Obama vocally support it (not to mention 80 percent of the American public). You’d be wrong. As it turns out, Big Pharma believes it has a trump card in its bid to maintain its inflated drug profits by keeping out competition from abroad. That trump card: the incompetence of the FDA. The argument is outlined in this op-ed piece by Peter Pitts, president... Read Full Story

Medicare: Thousands of Medicare Providers Abuse the Federal Tax System F.D.A. Issues Strictest Warning on Diabetes Drugs As America ages, the GREED factor related to Health Care grows exponentially. Services provided are watered down and cost is inflated to squeeze every penny out of the US Taxpayer. Health Care is no longer the realm of humanitarian motives. Health Care is BIG BUSINESS with roots in Pharmaceuticals and Hospital Corporations. The argument for and against the medical... Read Full Story

By Rob Fannon, editor, Phase 1 Investor Today, I want to tell you about a group of stocks ready to explode as the world’s largest drugmakers slim down… As I’ve explained before in Growth Stock Wire, Big Pharma is in trouble. The industry is facing slowing sales, patent expirations, generic competition, and withering pipelines. Now drugmakers are on a massive diet. The biggest losers – Pfizer, Merck, and Sanofi-Aventis – are dumping employees and slashing costs. One of the winners in this... Read Full Story

Big Pharma is in trouble. Generic competition, patent expirations and slowing sales are all eating into profits. So how can you turn a profit in this turbulent sector? By investing in contract research organisations, or CROs, says biotech expert Rob Fannon. When the big pharmaceutical companies outsource research to CROs they get paid whether or not the new drugs ever make it to market. There's another way to profit too - contract sales organizations, or CSOs. They're another way for Big... Read Full Story

Rep. Henry Waxman is currently investigating Big Pharma's off-label drug promotion (Waxman probes industry meeting with FDA). According to a statement Waxman made Tuesday, drug company representatives met with Food and Drug Administration officials last April to urge them to issue guidelines on distributing journal articles about off-label uses of products. Off-label uses are those that haven't been proven safe and effective. FDA developed a proposal along the lines suggested by industry... Read Full Story